Neos Therapeutics Inc. (NEOS) Stock Rating Lowered by Zacks Investment Research
Neos Therapeutics Inc. (NASDAQ:NEOS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.
According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
Separately, BMO Capital Markets initiated coverage on Neos Therapeutics in a report on Tuesday, June 28th. They set an “outperform” rating and a $15.00 target price for the company. Five research analysts have rated the stock with a buy rating, Neos Therapeutics has a consensus rating of “Buy” and an average target price of $20.94.
Neos Therapeutics (NASDAQ:NEOS) opened at 6.96 on Wednesday. Neos Therapeutics has a 52-week low of $6.33 and a 52-week high of $19.29. The firm’s 50-day moving average is $7.05 and its 200-day moving average is $8.66. The firm’s market capitalization is $111.85 million.
Neos Therapeutics (NASDAQ:NEOS) last posted its earnings results on Thursday, August 11th. The company reported ($1.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.16) by $0.49. Neos Therapeutics had a negative return on equity of 80.10% and a negative net margin of 968.81%. The firm had revenue of $1.49 million for the quarter, compared to analyst estimates of $1.48 million. On average, equities analysts expect that Neos Therapeutics will post ($5.39) earnings per share for the current year.
In related news, CFO Richard I. Eisenstadt purchased 3,710 shares of the company’s stock in a transaction that occurred on Thursday, August 25th. The stock was acquired at an average price of $6.82 per share, with a total value of $25,302.20. Following the completion of the purchase, the chief financial officer now directly owns 3,710 shares in the company, valued at $25,302.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.85% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp increased its position in Neos Therapeutics by 20.0% in the first quarter. State Street Corp now owns 64,825 shares of the company’s stock worth $698,000 after buying an additional 10,786 shares during the period. Geode Capital Management LLC increased its position in Neos Therapeutics by 5.4% in the first quarter. Geode Capital Management LLC now owns 38,698 shares of the company’s stock worth $417,000 after buying an additional 1,997 shares during the period. Bank of New York Mellon Corp increased its position in Neos Therapeutics by 73.1% in the second quarter. Bank of New York Mellon Corp now owns 38,008 shares of the company’s stock worth $353,000 after buying an additional 16,046 shares during the period. California State Teachers Retirement System increased its position in Neos Therapeutics by 140.1% in the second quarter. California State Teachers Retirement System now owns 28,815 shares of the company’s stock worth $267,000 after buying an additional 16,815 shares during the period. Finally, Vanguard Group Inc. increased its position in Neos Therapeutics by 12.3% in the second quarter. Vanguard Group Inc. now owns 293,989 shares of the company’s stock worth $2,729,000 after buying an additional 32,266 shares during the period. 37.73% of the stock is owned by institutional investors and hedge funds.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.